Anti-psychotic Medication (Stable Dose) Weight Loss Study
Primary Purpose
Obesity
Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
IHBG-10
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring obesity, weight loss, weight management, anti-psychotic medication, Zyprexa, Seroquel, Risperdal
Eligibility Criteria
Inclusion Criteria:
- Men and women, age 18 and older
- Agree to keep diet, exercise and all current health habits stable during participation in the study
- Currently on a stable dose of Risperdal (Risperidone), Seroquel (Quetiapine) and/or Zyprexa (Olanzapine) for at least three months
Exclusion Criteria:
- Current active acute psychotic episode
- Women who are pregnant, breastfeeding, or planning to become pregnant
- Prior bariatric surgery
- Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
- Obesity as a result of a clinically-diagnosed endocrine problem
Sites / Locations
- Avera Research Institute
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Arm Label
Control Group
Risperdal Group
Seroquel Group
Zyprexa Group
Arm Description
Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
Outcomes
Primary Outcome Measures
Weight
Secondary Outcome Measures
Body composition
Full Information
NCT ID
NCT01272765
First Posted
January 6, 2011
Last Updated
May 31, 2012
Sponsor
Avera McKennan Hospital & University Health Center
1. Study Identification
Unique Protocol Identification Number
NCT01272765
Brief Title
Anti-psychotic Medication (Stable Dose) Weight Loss Study
Official Title
Surveillance Study of Weight Response and Body Composition in Subjects Taking a Stable Dose of Risperdal, Seroquel, and/or Zyprexa for Greater Than 3 Months in Combination With 500 mg IHBG-10 TID
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Withdrawn
Why Stopped
Study did not get started.
Study Start Date
March 2012 (undefined)
Primary Completion Date
January 2013 (Anticipated)
Study Completion Date
January 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avera McKennan Hospital & University Health Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have been taking a stable dose of certain anti-psychotic medications for longer than three months.
Detailed Description
A total of 80 subjects will be enrolled in this study: 20 subjects will be randomized to receive placebo, and 60 will be randomized to receive the investigational product (20 who are on a stable dose of Seroquel, 20 who are on a stable dose of Risperdal, and 20 who are on a stable dose of Zyprexa). The investigational product or placebo will be taken 15 minutes prior to the three main meals of the day. Subjects will continue to take their prescribed anti-psychotic medications. Participation in this study involves four study visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
obesity, weight loss, weight management, anti-psychotic medication, Zyprexa, Seroquel, Risperdal
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control Group
Arm Type
Placebo Comparator
Arm Title
Risperdal Group
Arm Type
Experimental
Arm Description
Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
Arm Title
Seroquel Group
Arm Type
Experimental
Arm Description
Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
Arm Title
Zyprexa Group
Arm Type
Experimental
Arm Description
Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
sugar pill
Intervention Description
Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
IHBG-10
Other Intervention Name(s)
IHBG10
Intervention Description
500 mg IHBG-10
Primary Outcome Measure Information:
Title
Weight
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Body composition
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women, age 18 and older
Agree to keep diet, exercise and all current health habits stable during participation in the study
Currently on a stable dose of Risperdal (Risperidone), Seroquel (Quetiapine) and/or Zyprexa (Olanzapine) for at least three months
Exclusion Criteria:
Current active acute psychotic episode
Women who are pregnant, breastfeeding, or planning to become pregnant
Prior bariatric surgery
Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
Obesity as a result of a clinically-diagnosed endocrine problem
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edward Zawada, MD
Organizational Affiliation
Avera McKennan Hospital & University Health Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Avera Research Institute
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57105
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Anti-psychotic Medication (Stable Dose) Weight Loss Study
We'll reach out to this number within 24 hrs